Early vagal nerve stimulator implantation in children: personal experience and review of the literature
Data concerning the benefit of vagal nerve stimulation (VNS) in children under the age of 12 years is sparse. It was shown that reduction of seizure frequency and duration at an early age could lead to better psychomotor development. We therefore compare the outcome between early (≤ 5 years of age) and late (> 5 years of age) implantation of VNS in children.
This study is a prospective review of patients analyzing primarily the reduction of seizure frequency and secondarily epilepsy outcome assessed by the McHugh and Engel classification, reduction of antiepileptic drugs (AED), psychomotor development measured by the Vineland Adaptive Behavior Scale (VABS), and quality of life using the caregiver impression (CGI) scale. Mean follow-up time was 36 and 31 months in the early and late group, respectively.
Out of 12 consecutive VNS implantations for therapy refractory epilepsy, 5 were early implantations and 7 late implantations. Reduction of seizure frequency, McHugh and Engel classification, quality of life, psychomotor development and reduction of AED were comparable in both groups. One patient in the late group suffered from a postoperative infection resulting in explanation of the VNS device and re-implantation on the opposite side, while mortality rate was 0%.
VNS seems to be a safe and feasible therapy in children even under the age of 5 years. Responder rate, quality of life, and psychomotor development do not seem to be influenced by the child’s age at implantation; however, larger studies analyzing the outcome of early VNS implantation are warranted.
KeywordsEpilepsy Vagal nerve stimulator Vineland Adaptive Behavior Scale Drug-resistant epilepsy Psychomotor development Quality of life
We would like to thank Mrs. Marianne Schulz for her editorial help.
Compliance with ethical standards
The study protocol was approved by the local ethics committee (EKNZ, Basel, Switzerland).
Conflict of interest
The authors have no disclosures and no conflict of interest.
- 1.Elliott RE, Rodgers SD, Bassani L, Morsi A, Geller EB, Carlson C, Devinsky O, Doyle WK (2011) Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatr 7(5):491–500. https://doi.org/10.3171/2011.2.PEDS10505 CrossRefPubMedGoogle Scholar
- 14.Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E (2012) Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol 16(5):449–458. https://doi.org/10.1016/j.ejpn.2012.01.001 CrossRefPubMedGoogle Scholar
- 16.Colicchio G, Policicchio D, Barbati G, Cesaroni E, Fuggetta F, Meglio M, Papacci F, Rychlicki F, Scerrati M, Zamponi N (2010) Vagal nerve stimulation for drug-resistant epilepsies in different age, aetiology and duration. Childs Nerv Syst 26(6):811–819. https://doi.org/10.1007/s00381-009-1069-2 CrossRefPubMedGoogle Scholar
- 17.Sparrow SS BD, Cicchetti DV, Doll EA. (ed) (1984) Vineland adaptive behavior scales: interview edition, expanded form manual. 2nd ed.Circle Pines American Guidance Service, MinnGoogle Scholar
- 18.Orosz I, McCormick D, Zamponi N, Varadkar S, Feucht M, Parain D, Griens R, Vallee L, Boon P, Rittey C, Jayewardene AK, Bunker M, Arzimanoglou A, Lagae L (2014) Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia 55(10):1576–1584. https://doi.org/10.1111/epi.12762 CrossRefPubMedGoogle Scholar
- 20.Majoie HJ, Berfelo MW, Aldenkamp AP, Evers SM, Kessels AG, Renier WO (2001) Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol 18(5):419–428. https://doi.org/10.1097/00004691-200109000-00006 CrossRefPubMedGoogle Scholar